Ratios Reveal: Breaking Down Astrazeneca plc ADR (AZN)’s Financial Health

The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Astrazeneca plc ADR (NASDAQ: AZN) closed the day trading at $78.56 up 0.18% from the previous closing price of $78.42. In other words, the price has increased by $0.18 from its previous closing price. On the day, 3.83 million shares were traded. AZN stock price reached its highest trading level at $78.78 during the session, while it also had its lowest trading level at $78.185.

Ratios:

For a better understanding of AZN, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 30.37 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 28.72. For the most recent quarter (mrq), Quick Ratio is recorded 0.70 and its Current Ratio is at 0.89. In the meantime, Its Debt-to-Equity ratio is 0.92 whereas as Long-Term Debt/Eq ratio is at 0.75.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on May 30, 2024, initiated with a Buy rating and assigned the stock a target price of $97.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AZN now has a Market Capitalization of 244719894528 and an Enterprise Value of 148418445312. As of this moment, Astrazeneca’s Price-to-Earnings (P/E) ratio for their current fiscal year is 38.72, and their Forward P/E ratio for the next fiscal year is 16.77. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.85. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.12 while its Price-to-Book (P/B) ratio in mrq is 6.22. Its current Enterprise Value per Revenue stands at 3.117 whereas that against EBITDA is 9.392.

Stock Price History:

The Beta on a monthly basis for AZN is 0.47, which has changed by 0.089295626 over the last 52 weeks, in comparison to a change of 0.2586832 over the same period for the S&P500. Over the past 52 weeks, AZN has reached a high of $80.86, while it has fallen to a 52-week low of $60.47. The 50-Day Moving Average of the stock is 3.79%, while the 200-Day Moving Average is calculated to be 14.91%.

Shares Statistics:

Over the past 3-months, AZN traded about 4.98M shares per day on average, while over the past 10 days, AZN traded about 3192100 shares per day. A total of 3.10B shares are outstanding, with a floating share count of 3.10B. Insiders hold about 0.02% of the company’s shares, while institutions hold 16.04% stake in the company. Shares short for AZN as of 1715731200 were 7665396 with a Short Ratio of 1.34, compared to 1713139200 on 8578408.

Dividends & Splits

AZN’s forward annual dividend rate is 1.45, up from 2.9 a year ago. Against a Trailing Annual Dividend Yield of 0.036980364The stock’s 5-year Average Dividend Yield is 2.46. The current Payout Ratio is 73.87% for AZN, which recently paid a dividend on 2024-02-22 with an ex-dividend date of 1708560000. Stock splits for the company last occurred on 2015-07-27 when the company split stock in a 2:1 ratio.

Most Popular